Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MURA Stock Forecast 2026-2027
$2.04
Current Price
$35.38M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MURA Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
MURA Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-18.1%
1 Year Change
0.0%
Year-to-Date Change
-57.0%
From 52W High of $4.74
+114.7%
From 52W Low of $0.95
📊 TOP ANALYST CALLS
Did MURA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mural Oncology is one of their latest high-conviction picks.
Latest MURA Stock Price Targets & Analyst Predictions
MURA has shown a year-to-date change of 0.0% and a 1-year change of -18.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MURA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MURA Analyst Ratings
0
Buy
1
Hold
0
Sell
MURA Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.04
Latest MURA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MURA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Maintains | $6.00 |
| Mar 25, 2025 | Jones Trading | Soumit Roy | Hold | Downgrade | $N/A |
| Mar 12, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $18.00 |
| Jan 27, 2025 | Jones Trading | Soumit Roy | Buy | Initiates | $16.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $18.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $18.00 |
| Oct 17, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Initiates | $18.00 |
| Oct 4, 2024 | Raymond James | Laura Prendergast | Strong Buy | Initiates | $18.00 |
| Jun 28, 2024 | Rodman & Renshaw | Tony Butler | Buy | Initiates | $15.00 |
| Apr 4, 2024 | Morgan Stanley | Judah Frommer | Overweight | Initiates | $13.00 |
Mural Oncology plc (MURA) Competitors
The following stocks are similar to Mural Oncology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MURA
Mural Oncology
mkt cap
35.38M
Mural Oncology plc (MURA) Financial Data
Mural Oncology plc has a market capitalization of $35.38M with a P/E ratio of -0.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -103.9%.
Valuation Metrics
Market Cap
$35.38M
Enterprise Value
$-19,941,248
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+166.4%
Current Ratio
5.9x
Debt/Equity
6.4x
ROE
-103.9%
ROA
-49.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mural Oncology plc (MURA) Business Model
About Mural Oncology plc
What They Do
Develops innovative cancer therapies.
Business Model
The company focuses on creating and commercializing novel biopharmaceutical therapies aimed at treating various cancers. It generates revenue through the development of precision medicine solutions, which are tailored using genetic and molecular profiling to improve treatment efficacy and reduce side effects.
Additional Information
Mural Oncology is positioned as a vital contributor to advancements in cancer research and therapy development, addressing significant unmet medical needs in the oncology space. Its commitment to personalized healthcare not only enhances patient outcomes but also plays a crucial role in reducing cancer mortality rates, reaffirming its importance in the biotech industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
116
CEO
Ms. Caroline J. Loew Ph.D.
Country
Ireland
IPO Year
2023
Website
www.muraloncology.comMural Oncology plc (MURA) Latest News & Analysis
Latest News
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
7 months ago
Quick Summary
Mural Oncology plc (Nasdaq: MURA) has completed a scheme of arrangement to be acquired by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA), effective December 5, 2025.
Why It Matters
Mural Oncology is being acquired by XOMA Royalty, impacting its stock value and potential future performance, which could influence shareholder decisions and market sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mural Oncology plc (Nasdaq: MURA) announced that the High Court of Ireland has approved its acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA).
Why It Matters
The court-sanctioned acquisition of Mural by XOMA Royalty indicates a strategic consolidation, potentially impacting Mural's stock value and investor sentiment regarding future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
7 months ago
Quick Summary
Mural Oncology (Nasdaq: MURA) confirmed that the Additional Price Per Share is $0.000, leading to a total cash consideration of $2.035 per share for shareholders upon closing the acquisition.
Why It Matters
Mural Oncology's cash payout of $2.035 per share signals a definitive outcome from its acquisition agreement, impacting shareholder value and market perception of MURA and XOMA.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The news excerpt indicates a restriction on the release, publication, or distribution of information in certain jurisdictions due to legal regulations.
Why It Matters
This news excerpt indicates potential regulatory issues or legal barriers affecting the distribution of financial information, signaling increased risk for investors in that jurisdiction.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mural Oncology plc (Nasdaq: MURA) has published a definitive proxy statement regarding an acquisition, in compliance with Irish Takeover Rules, and is mailing it to shareholders.
Why It Matters
Mural Oncology's definitive proxy statement signals a potential acquisition, which may impact shareholder value, stock price volatility, and future company direction.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mural Oncology plc (NASDAQ: MURA)
10 months ago
Quick Summary
Monteverde & Associates PC, a top class action firm, is investigating Mural Oncology plc (NASDAQ: MURA) regarding its sale to XOMA Royalty Corporation.
Why It Matters
The investigation into Mural Oncology's sale could impact its stock price and shareholder value, signaling potential risks or opportunities for investors in MURA.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MURA Stock
What is Mural Oncology plc's (MURA) stock forecast for 2027?
Analyst forecasts for Mural Oncology plc (MURA) are not currently available. The stock is trading at $2.04.
Is MURA stock a good investment in 2027?
According to current analyst ratings, MURA has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MURA stock?
Price predictions from Wall Street analysts for MURA are not currently available. The stock is trading at $2.04.
What is Mural Oncology plc's business model?
The company focuses on creating and commercializing novel biopharmaceutical therapies aimed at treating various cancers. It generates revenue through the development of precision medicine solutions, which are tailored using genetic and molecular profiling to improve treatment efficacy and reduce side effects.
What is the highest forecasted price for MURA Mural Oncology plc?
Price targets from Wall Street analysts for MURA are not currently available. The stock is trading at $2.04.
What is the lowest forecasted price for MURA Mural Oncology plc?
Price targets from Wall Street analysts for MURA are not currently available. The stock is trading at $2.04.
What is the overall MURA consensus from analysts for Mural Oncology plc?
The overall analyst consensus for MURA is neutral. Out of 5 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are MURA stock price projections?
Stock price projections, including those for Mural Oncology plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 10:40 AM UTC